Log in

Relevant bibliographies by topics / And macitentan

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers
Reports

Academic literature on the topic 'And macitentan'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'And macitentan.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "And macitentan"

1

Martynyuk, T. V., and A. M. Aleevskaya. "Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan." Kardiologiia 60, no. 7 (2020): 28–35. http://dx.doi.org/10.18087/cardio.2020.7.n1136.

Full text

Abstract:

Aim To compare results of 24-h treatments with bosentan and macitentan by the clinical functional status and indexes of pulmonary hemodynamics in patients with pulmonary arterial hypertension (PAH).Materials and methods Based on the Russian National Registry (NCT03707561), 44 patients older than 18 years with PAH (34 patients with idiopathic pulmonary hypertension (IPH) and 10 patients with Eisenmenger syndrome) were retrospectively included into this study. Based on the statistical method of pairwise comparison, two groups were formed and matched by age, gender, WHO functional class (FC), and

APA, Harvard, Vancouver, ISO, and other styles

2

Rahaghi, Franck F., Hassan M. Alnuaimat, Rana L. A. Awdish, et al. "Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document." Pulmonary Circulation 7, no. 3 (2017): 702–11. http://dx.doi.org/10.1177/2045893217721695.

Full text

Abstract:

In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a

APA, Harvard, Vancouver, ISO, and other styles

3

Tynan, Timothy, Kathryn Hird, Tara Hannon, and Eli Gabbay. "Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan." Journal of International Medical Research 47, no. 5 (2019): 2177–86. http://dx.doi.org/10.1177/0300060519840130.

Full text

Abstract:

Objectives To assess whether switching patients with suboptimally controlled pulmonary arterial hypertension from bosentan or ambrisentan to macitentan would improve six-minute walk test (6MWT) distance and World Health Organization functional class. Methods This was a retrospective cohort analysis of 37 patients from a single center. Patients were separated into three heterogeneous treatment groups and followed for 18 months: switch group (n = 14): patients switched to macitentan from bosentan/ambrisentan; added group (n = 11): patients who began macitentan as de novo therapy (n = 5) or who a

APA, Harvard, Vancouver, ISO, and other styles

4

Martynuk, T. V., S. N. Nakonechnikov, and I. Ye Chazova. "MACITENTAN: THE EVOLUTION OF THE CLASS ENDOTHELIN RECEPTOR ANTAGONISTS TO IMPROVE EFFICACY AND SAFETY OF PAH TREATMENT." Eurasian heart journal, no. 2 (June 30, 2013): 15–26. http://dx.doi.org/10.38109/2225-1685-2013-2-15-26.

Full text

Abstract:

Pulmonary arterial hypertension (PAH) is a severe progressive disease, characterized by advanced remodeling of small pulmonary arteries and arterioles, which ultimately leads to right heart failure and death. Due to discovery of PAH pathophysiological targets, new medications have been developed and implemented into clinical practice. These medications compensate the deficiencies of endogenous prostacyclin and nitric oxide and also block the effects of endothelin-1 (ET-1). The role of the latter in PAH pathophysiology is related to its strong vasoconstrictory properties, as well as to a number

APA, Harvard, Vancouver, ISO, and other styles

5

Hanibuchi, Masaki, Sun-Jin Kim, Kenji Otsuka, et al. "Eradication of experimental brain metastases of human non-small cell lung cancer by macitentan, a dual antagonist of the endothelin A and B receptor, combined with paclitaxel." Journal of Clinical Oncology 30, no. 30_suppl (2012): 92. http://dx.doi.org/10.1200/jco.2012.30.30_suppl.92.

Full text

Abstract:

92 Background: Treatment of patients with lung cancer brain metastases remains a major challenge because of the limited availability of standard therapy. Thus, the development of successful treatment options for these patients is mandatory. Recently, the endothelin axis was reported to be involved in cancer progression through its pleiotropic biological effects on cell survival, proliferation, invasion, and metastasis. Methods: In this study, we evaluated both the in vitro and in vivoeffects of macitentan, an orally bioavailable, dual endothelin A receptor and endothelin B receptor antagonist,

APA, Harvard, Vancouver, ISO, and other styles

6

Shinohara, Tsutomu, Hirofumi Sawada, Shoichiro Otsuki, et al. "Macitentan reverses early obstructive pulmonary vasculopathy in rats: early intervention in overcoming the survivin-mediated resistance to apoptosis." American Journal of Physiology-Lung Cellular and Molecular Physiology 308, no. 6 (2015): L523—L538. http://dx.doi.org/10.1152/ajplung.00129.2014.

Full text

Abstract:

It remains unknown whether current disease-targeting therapy can histologically reverse obstructive pulmonary vasculopathy and how the timing of the therapy influences the antiremodeling effects of the compound. We test the hypothesis that a novel endothelin receptor antagonist macitentan reverses the early and/or late stages of occlusive pulmonary vascular disease (PVD) in rats. Rats with pulmonary arterial hypertension (PAH), which were produced by combined exposure to a vascular endothelial growth factor receptor inhibitor Sugen 5416 and hypobaric hypoxia for 3 wk, were assigned to receive

APA, Harvard, Vancouver, ISO, and other styles

7

Martynyuk, T. V., S. N. Nakonechnikov, and I. Ye Chazova. "OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS." Eurasian heart journal, no. 2 (June 30, 2017): 20–27. http://dx.doi.org/10.38109/2225-1685-2017-2-20-27.

Full text

Abstract:

Modern concepts of pulmonary arterial hypertension (PAH) pathogenesis focus on the key role of endothelial dysfunction of pulmonary vessels. To control the activation of endothelin-1 system, endothelin receptor antagonists (ERA) are current ly used. Until recently, this class of drugs in our country and abroad was represented by two drugs: the sulfonamide derivative - a nonselective ERA bosentan and a non-sulfonamide derivative - ambrisentan, which blocks only ETA-receptors. Not the selectivity of ERAs, but their pharmacokinetic characteristics determine the differences in the profile of effic

APA, Harvard, Vancouver, ISO, and other styles

8

Trivedi, Jahanvee K., Chirag J. Patel, and M. M. Patel. "RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF MACITENTAN WITH ITS KNOWN AND UNKNOWN DEGRADATION IMPURITIES IN ITS TABLET DOSAGE FORM." International Journal of Applied Pharmaceutics 10, no. 5 (2018): 81. http://dx.doi.org/10.22159/ijap.2018v10i5.26211.

Full text

Abstract:

Objective: To develop and validate macitentan with its known and unknown degradation impurities in its tablet dosage form.Methods: The RP-HPLC method for macitentan and its impurities was developed and three potential degradation impurities MCA-02, MCA-01 and degradation impurity and N-propyl derivative and N-N dimethyl derivative process impurities were separated. Chromatographic separation was achieved within 70 min on Inertsil C8 (250*4.6 mm, 5 µm) column, Using mobile phase A [Ammonium acetate (ph 4.5 adjusted with glacial acetic acid)] and mobile phase B acetonitrile in gradient elution.

APA, Harvard, Vancouver, ISO, and other styles

9

Vachiéry, Jean-Luc, Marion Delcroix, Hikmet Al-Hiti, et al. "Macitentan in pulmonary hypertension due to left ventricular dysfunction." European Respiratory Journal 51, no. 2 (2018): 1701886. http://dx.doi.org/10.1183/13993003.01886-2017.

Full text

Abstract:

The MELODY-1 study evaluated macitentan for pulmonary hypertension because of left heart disease (PH-LHD) in patients with combined post- and pre-capillary PH.63 patients with PH-LHD and diastolic pressure gradient ≥7 mmHg and pulmonary vascular resistance (PVR) >3WU were randomised to macitentan 10 mg (n=31) or placebo (n=32) for 12 weeks. The main end-point assessed a composite of significant fluid retention (weight gain ≥5% or ≥5 kg because of fluid overload or parenteral diuretic administration) or worsening in New York Heart Association functional class from baseline to end of treatmen

APA, Harvard, Vancouver, ISO, and other styles

10

Qin, Jinlv, Guizuo Wang, and Dong Han. "Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Global Heart 18, no. 1 (2023): 58. http://dx.doi.org/10.5334/gh.1274.

Full text

Abstract:

Background: This systematic review and meta-analysis aimed to determine the efficacy of macitentan in patients with pulmonary hypertension (PH). Methods: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of PH with macitentan, compared with placebo or blank, were reviewed. Studies were pooled to weighted mean differences (WMDs) and risk ratios (RRs), with 95% confidence intervals (CIs). Results: Six RCTs (enrolling 1,003 participants) met the inclusion criteria. Macitentan sh

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "And macitentan"

1

BARTOLUCCI, ROBERTA. "Optimal design in pediatric clinical trials: theory and application to the macitentan case study." Doctoral thesis, Università degli studi di Pavia, 2021. http://hdl.handle.net/11571/1420336.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Drozd, Katarzyna. "The Effects of a Novel Endothelin Receptor Antagonist, Macitentan, on Right Ventricular Substrate Utilization and Function in a Sugen5416/Hypoxia Rat Model of Severe Pulmonary Artery Hypertension." Thesis, Université d'Ottawa / University of Ottawa, 2014. http://hdl.handle.net/10393/32066.

Full text

Abstract:

Background-Pulmonary artery hypertension (PAH) is characterized by progressive vascular changes causing increased pulmonary resistance and eventual right heart failure (HF). It has been suggested that altered myocardial substrate utilization may be associated with right HF, however these changes have not yet been well characterized. The aim of this study was to evaluate in vivo right ventricular (RV) function and RV glucose and fatty acid metabolism in an experimental model of PAH using non-invasive positron emission tomography (PET) imaging and to investigate the effect of a novel endothelin

APA, Harvard, Vancouver, ISO, and other styles

3

Roohani, Siyer [Verfasser]. "Der Endothelinrezeptorantagonist Macitentan verbessert die Isosorbid-5-Mononitrat (ISMN) und Isosorbiddinitrat (ISDN)-induzierte endotheliale Dysfunktion, oxidativen Stress und vaskuläre Inflammation / Siyer Roohani." Mainz : Universitätsbibliothek der Johannes Gutenberg-Universität Mainz, 2021. http://d-nb.info/1224810570/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Lachaux, Marianne. "Nouvelles cibles pharmacologiques du traitement de la dysfonction cardiovasculaire associée au syndrome métabolique." Thesis, Normandie, 2019. http://www.theses.fr/2019NORMR010.

Full text

Abstract:

Le syndrome métabolique (SM) est associé avec une augmentation du risque de survenue d’évènements cardiovasculaires et plus particulièrement d’insuffisance cardiaque à fraction d’éjection préservée (ICFEp). L’ICFEp représente environ 50% des IC totales, cependant, à ce jour, aucun traitement n’a permis de diminuer significativement la mortalité. L’ICFEp associée au SM, bien que d’origine multifactorielle, est caractérisée par une activation du système endothélinergique, une surexpression du récepteur minéralocorticoïde ainsi qu’une dysfonction mitochondriale participant à l’établissement et au

APA, Harvard, Vancouver, ISO, and other styles

5

Li, Shanpeng. "Novel pathways of heart failure with preserved ejection fraction." Thesis, 2015. https://hdl.handle.net/2144/16263.

Full text

Abstract:

INTRODUCTION: Diastolic heart failure (HF) i.e., HF with preserved ejection fraction (HFpEF) accounts for ~50% of all clinical HF presentations; but unlike systolic HF i.e., HF with reduced ejection fraction (HFrEF), there are no evidenced based therapies. Obesity is commonly associated with HFpEF. However, there exist a sub-group of obese patients that exhibit a higher survival rate to HFpEF as compared to average patients. Hypertension is the most important risk factor for HFpEF, with a prevalence of 60-89% reported by large controlled trials, epidemiological studies and HF registries. HFpEF

APA, Harvard, Vancouver, ISO, and other styles

6

Costa, Bruna Cláudia Marques. "Potencial terapêutico dos antagonistas da endotelina." Master's thesis, 2018. http://hdl.handle.net/10284/7358.

Full text

Abstract:

A Endotelina é um péptido produzido essencialmente pelas células endoteliais em resposta a vários estímulos, sendo considerado o péptido vasoconstritor mais potente. A endotelina liga-se a dois recetores acoplados à proteína G, o recetor ETA e o recetor ETB. O recetor ETA predomina a nível do músculo liso vascular e a sua ativação provoca essencialmente vasoconstrição, por sua vez o recetor ETB tem maior expressão a nível do endotélio e a sua ativação provoca vasodilatação, podendo também em menor grau relativamente ao ETA, causar vasoconstrição. Em condições patológicas ocorre a desregu

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "And macitentan"

1

"MACITENTAN." In Litt's Drug Eruption and Reaction Manual. CRC Press, 2015. http://dx.doi.org/10.1201/b17996-81.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

"Macitentan." In Hale’s Medications & Mothers’ Milk™ 2019. Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bolli, M. H., C. Boss, J. Gatfield, M. Iglarz, and A. Treiber. "The Discovery of Macitentan—A Standard Medicinal Chemistry Program?" In Comprehensive Medicinal Chemistry III. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-12-409547-2.12455-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "And macitentan"

1

Voors, Adriaan, and Robert van den Heuvel. "SERENADE: Macitentan fails in HFpEF plus PAH." In Heart Failure 2022, edited by Adriaan Voors and Marc Bonaca. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/596ea84f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tsagkaris, Iraklis, Eleni Vrigkou, Dimitris Konstantonis, et al. "Switching to macitentan in pulmonary arterial hypertension." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa3045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hurst, Noémie, Matthias Pellek, Patricia N. Sidharta, and Jasper Dingemanse. "Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Marinescu, D., D. Christiansen, J. Thenganatt, and J. T. Granton. "Initial Combination Therapy with Macitentan and Tadalafil in Pulmonary Arterial Hypertension." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3827.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kim, Nick, Richard Channick, Vallerie Mclaughlin, et al. "Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.oa4945.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hamilton, Neil, Michaela Sellars, Mark Graves, et al. "Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa3791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tent, Michiel. "Fixed-dose macitentan plus tadalafil superior to either agent alone in PAH." In ACC 2023 Scientific Session, edited by Marc Bonaca. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/e5b26129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kim, Nick, Kelly Chin, Vallerie Mclaughlin, et al. "Macitentan in portopulmonary hypertension (PoPH): Real-world data from OPUS and OrPHeUS." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa5457.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Zebadua, R., J. C. López, N. G. Zayas, et al. "Long-term clinical assessment in patients with Eisenmenger Syndrome treated with macitentan." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.4261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Santos, Mario, Fabienne Gonçalves, Luísa Carvalho, and Abílio Reis. "Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa3536.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "And macitentan"

1

Wang, Jing, Xu Liu, Lihui Ge, and Dongmei Pei. Efficacy and safety of macitentan for pulmonary hypertension: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.8.0042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!